Tricida fetches $57.5 mln Series D
South San Francisco, California-based Tricida, Inc, a developer of oral drug therapies, has raised $57.5 million in Series D financing. The investors were Wellington Management Company LLP, Venrock Healthcare Capital Partners, Cormorant Asset Management, OrbiMed, Longitude Capital, Sibling Capital Ventures, Limulus Venture Partners and Vivo Capital.
8 November 2017•1 min read
